St. Jude Daig Division Splits To Emphasize Vascular Closure, AF Devices
This article was originally published in The Gray Sheet
Executive Summary
Newly appointed president of St. Jude Medical's cardiology division Paul Buckman will work to retain AngioSeal's number-one position in the U.S. vascular closure device market as newcomer Abbott Labs tries to gain ground
You may also be interested in...
St. Jude Sees Multiple Growth Opportunities For Vascular Access Closure
St. Jude Medical is counting on increases in atrial fibrillation ablation, aneurysm repair and minimally invasive valve implants to expand the market for its femoral artery access closure devices
St. Jude Sees Multiple Growth Opportunities For Vascular Access Closure
St. Jude Medical is counting on increases in atrial fibrillation ablation, aneurysm repair and minimally invasive valve implants to expand the market for its femoral artery access closure devices
St. Jude PFO Program For Stroke, Migraine Gets Boost With Velocimed Deal
St. Jude Medical will accelerate its patent foramen ovale (PFO) R&D program for stroke treatment by acquiring Velocimed for more than $82.5 mil. under a definitive agreement, the firms said Feb. 15